智通财经APP讯，翰森制药(03692)发布公告，于2025年8月27日完成配售1.08亿股。 ...

Group 1 - The company Hansoh Pharmaceutical (03692) announced the completion of a placement of 108 million shares on August 27, 2025 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 翰森製藥集團有限公司 FF305 呈交日期： 2025年8月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 03692 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | ...

Market Overview - The Hong Kong stock market experienced a significant decline in the afternoon, with the Hang Seng Index dropping by 1.27%, losing over 300 points. The Hang Seng China Enterprises Index and the Hang Seng Tech Index fell by 1.4% and 1.47% respectively, with the former barely holding above the 9000-point mark [2] - Major technology stocks, which serve as market indicators, continued to decline in the afternoon. Kuaishou and Meituan fell over 3%, while JD.com dropped by 2.5%. Baidu, NetEase, and Tencent saw declines close to 2%, and Xiaomi fell by 0.56%. Alibaba managed to stay slightly positive [3] Sector Performance - The financial sector, including banks, insurance companies, and Chinese brokerage firms, collectively underperformed, contributing to the overall market decline. The performance of individual stocks continued to be affected by ongoing earnings reports, with property management and real estate stocks experiencing significant drops [3] - Biopharmaceutical stocks faced a collective downturn, particularly in the innovative drug sector, following comments from Trump regarding the rapid imposition of tariffs on pharmaceuticals. This led to notable declines in various biopharma stocks [3] Specific Stock Movements - Several biopharmaceutical companies saw substantial declines, including Kanghao Ya-B (-8.59%), Qiansirui Biotechnology (-7.42%), and Kangfang Biotechnology (-7.10%). Other notable decliners included Xiansheng Pharmaceutical (-6.79%) and Shiyao Group (-6.36%) [3] - In contrast, the rare earth sector remained strong, benefiting from the implementation of supply reforms and multiple catalysts. Apple’s upcoming event on September 9, where the iPhone 17 series is expected to be launched, led to a rise in Apple-related stocks, with Lens Technology (300433) surging nearly 8% and reaching a new high since its listing [4]

恒生指数、恒生科技指数双双转跌，华润万象生活跌超8.5％，翰森制药、石药集团、申洲国际、李宁 等均跌4％。 (本文来自第一财经) ...

Core Viewpoint - The Hong Kong stock market for innovative drugs is experiencing a pullback, with the Hang Seng Hong Kong Stock Connect Innovative Drug Selective Index down by 2.31%, and most constituent stocks also declining [1]. Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug ETF (520880) opened high but fell by 1.97% during the session, indicating a downward trend despite a positive buying attitude reflected in a real-time premium rate of 0.4% [1]. - Year-to-date until July 31, the Hang Seng Hong Kong Stock Connect Innovative Drug Selective Index has increased by 101.58%, outperforming the Hang Seng Index (23.50%) and the Hang Seng Technology Index (22.05%) by 78.08 and 79.53 percentage points respectively [5]. Group 2: Future Outlook - Despite recent volatility in innovative drug sentiment, there are continuous catalysts for the sector, including mid-year performance reports, industry conference data, potential business development transactions, and the advancement of commercial insurance directories [3]. - With expectations of interest rate cuts in the U.S., the valuation framework for innovative drugs is likely to improve [3]. - The improvement in liquidity narratives suggests that the Hong Kong stock market may experience a phase of rebound, narrowing the gap with the rapidly rising A-share market [3]. Group 3: Investment Strategy - The current earnings forecast rate for the Hong Kong stock market is at its highest since 2022, suggesting a favorable environment for investment [3]. - It is recommended to focus on innovative drugs first, followed by the internet sector, and finally new consumption, as the latter awaits macroeconomic and profit turning points [3].

Group 1 - The Hong Kong innovative drug concept stocks have declined, with companies such as 3SBio and Hansoh Pharmaceutical dropping over 4%, while Innovent Biologics, CSPC Pharmaceutical Group, and China National Pharmaceutical Group fell over 3% [1] - The Hang Seng Innovative Drug ETF has decreased nearly 2% due to market influences [1] Group 2 - Several ETFs related to innovative drugs have shown declines, with specific prices and percentage drops noted, such as the Hang Seng Innovative Drug ETF at 1.597, down 1.90% [2] - A brokerage firm indicated that the collection of chemical drugs has completed ten batches, with the new batch increasing quality requirements and reflecting a reduction in "involution," leading to a diminishing marginal impact [2] - The Pharma collection is gradually clearing out, entering a period of innovative transformation and harvest, with favorable medical insurance policies expected to support rapid growth of innovative drugs [2]

Group 1 - The biopharmaceutical sector is currently active, with the Biopharmaceutical ETF (159859) showing a slight increase of 0.23% and a trading volume exceeding 48 million yuan, indicating strong investor interest [1] - The Biopharmaceutical ETF (159859) closely tracks the National Biopharmaceutical Index (399441.SZ), covering various sectors such as innovative drugs, CXO, vaccines, and blood products, making it the largest and most liquid product in its category [1] - The Innovation Drug ETF Tianhong (517380) has seen a slight decline of 0.24% but has recorded a net inflow of over 22.56 million yuan over the past five trading days, reflecting ongoing investor confidence [1] Group 2 - The Chinese government has approved a plan to develop the Jiangsu Free Trade Zone into a globally influential biopharmaceutical industry hub, enhancing its international competitiveness [2] - Major innovative pharmaceutical companies have reported strong performance in their 2025 semi-annual reports, with Heng Rui Pharmaceutical achieving a revenue of 15.76 billion yuan, a year-on-year increase of 15.88%, and a net profit of 4.45 billion yuan, up 29.67% [2] - The domestic innovative drug industry is entering a phase of performance realization after a decade of development, with a focus on the upcoming policy changes and the establishment of a new pricing mechanism for newly launched drugs [3]

Investment Rating - The report maintains an "Outperform" rating for Hansoh Pharma with a target price of HKD 44.32, based on a current price of HKD 37.66 [2][7]. Core Insights - Hansoh Pharma's revenue for 1H25 reached CNY 7.4 billion, representing a year-on-year growth of 14%, with innovative drug sales contributing CNY 6.1 billion, up 22% year-on-year. Collaboration revenue was CNY 1.66 billion, an 18% increase year-on-year [3][12]. - The management has raised the full-year revenue guidance to high double digits, reflecting strong performance and expectations for continued growth [3][12]. Financial Performance - Revenue projections for FY25, FY26, and FY27 have been adjusted to CNY 14.7 billion, CNY 16.0 billion, and CNY 17.7 billion respectively, with net profit estimates of CNY 5.0 billion, CNY 5.1 billion, and CNY 5.7 billion [7][13]. - The gross profit margin (GPM) for 1H25 was reported at 91.1%, remaining stable compared to the previous year [3][12]. Segment Performance - The oncology segment generated CNY 4.5 billion, accounting for 61% of total revenue, driven by the strong sales of Aumolertinib, which received approvals for new indications [4][15]. - The anti-infection segment contributed CNY 740 million, while the central nervous system segment generated CNY 770 million, and the metabolism and other diseases segment accounted for CNY 1.4 billion [15][13]. Key Catalysts - Upcoming catalysts for Hansoh Pharma include the inclusion of Aumolertinib in the National Reimbursement Drug List (NRDL) and the anticipated approval of its combination with chemotherapy for NSCLC [4][15]. - The company has received approximately CNY 850 million in milestone revenue, exceeding previous management guidance, indicating a potential for sustainable revenue growth from future milestones [15][13].

Core Viewpoint - The valuation of weight loss drug companies is under scrutiny as the market faces a reality check in 2025, following a period of rapid growth and inflated expectations driven by the success of GLP-1 drugs [1][4]. Group 1: Market Dynamics - The weight loss drug sector has seen intense competition, particularly with the rise of oral small molecule GLP-1 drugs, which are favored for their cost and adherence advantages [1]. - Merck's acquisition of a preclinical oral small molecule GLP-1 from Hansoh Pharma involved an upfront payment of $112 million, with potential milestone payments reaching $1.9 billion [1]. - Metsera, the first biotech company to go public in the weight loss drug space, saw its stock surge nearly 50% on its debut, achieving a market cap of over $3.4 billion within three years of its establishment [1]. Group 2: Clinical Challenges - As clinical sample sizes increase and treatment durations extend, weight loss drugs are revealing significant shortcomings, including side effects and reduced efficacy [2][3]. - Viking's oral GLP-1 drug VK2735 initially showed promising results but faced a 42% stock drop after final clinical results revealed a high dropout rate due to side effects [5][6]. - Eli Lilly's Orforglipron also underperformed expectations, leading to a 14.14% drop in stock price, marking its largest single-day decline since 2000 [6]. Group 3: Safety and Efficacy Concerns - The transition from early clinical trials to larger populations often exposes new safety issues, as seen with Pfizer's decision to halt the development of Danuglipron due to potential liver damage concerns [8]. - Novo Nordisk's downward revision of its 2025 sales growth forecast from 13%-21% to 8%-14% resulted in a 21.8% stock drop, indicating market sensitivity to performance expectations [9]. Group 4: Domestic Market Outlook - Domestic weight loss drug companies are still in the early stages of development, with many relying on promising early data from animal studies to secure funding [10][11]. - The path from animal studies to human trials is fraught with challenges, and the reliance on existing drug frameworks raises concerns about safety and efficacy in later-stage trials [11][14]. Group 5: Future Survival Strategies - The next generation of weight loss drugs will face high standards for efficacy, and slight deviations in performance may not be sufficient to differentiate products in a competitive market [15]. - The industry is moving towards maturity, with ongoing innovation in areas such as weight loss and muscle gain, despite the challenges posed by clinical validation [15][16]. - Companies must prepare for a landscape where only clinically validated therapies can thrive in a market projected to be worth hundreds of billions [17].